If you have been reading about GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Your excellency, Mr President, I greet you in the name of the many thousands of people in Britain who stood against the tide and opposed the war ... I greet you too in the name of the Palestinian people ... I thought the president would appreciate knowing that even today, three years after the war, I still meet families who are calling their newborn sons Saddam ... Sir, I salute your courage, your strength, your indefatigability. And I want you to know that we are with you until victory, until victory, until Jerusalem (hatta al-nasr, hatta al-nasr, hatta al-Quds). During Galloway's 2004 defamation case against the Daily Telegraph, the paper's defence Queen's Counsel accused Galloway of having "fawned over" Saddam during their meeting in 1994. Labour leader John Smith said: "I deeply deplore the foolish statement made in Iraq by Mr. George Galloway. In no way did he speak for the Labour Party and I wholly reject his comments". Galloway said that he was saluting the Iraqi people, rather than Saddam Hussein, and Galloway's friend Anas Altikriti observed that this is how it was translated for Saddam. Shortly after his return, Galloway was given a "severe reprimand" and "final warning" by the Labour Chief Whip, Derek Foster. Galloway apologised for his conduct and undertook to follow future instruction from the whips. For his meeting with Saddam, Galloway was dubbed the "MP for Baghdad North". When he spoke before the U.S.
=== Gene therapy === Gene therapy for hemoglobinopathies was first trialled in 2014 on a single patient with sickle cell disease (a fault in the beta globin gene), and followed by clinical trials in which a number of patients with either sickle cell or beta thalassemia were successfully treated. Gene therapies work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel with this, the person with thalassemia disease undergoes a myeloablation procedure (a form of chemotherapy) to destroy the remaining HSCs in their bone marrow. The laboratory treated cells are then infused back into the patient where they colonise the bone marrow and eventually commence production of healthy blood cells. There are fewer risks from this procedure than from HSCT, since the transplanted cells are autologous having originated from the patient herself/himself. There are two approved forms of gene therapy for beta thalassemia. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia which adds a healthy beta-globin gene to the HSCs. It was approved for medical use in the United States in August 2022. The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. In the laboratory, these HSCs then have a new gene for T87Q-globin (a modified beta-globin) introduced to them using a lentiviral vector.
== Early career == Starting in the 1970s Smith published peer-reviewed papers on several subjects, including mass spectrometry, ion cyclotron resonance mass spectrometry, ion-molecule reactions, molecular assemblies, and supercritical fluid solutions. This early work has led him to be considered an internationally recognized expert in mass spectrometry and separation techniques, and his research has led to advancements in instrumentation for the medical and environmental analysis fields, as well as biological research. In the medical field, Smith's work has produced benefits in the areas of drug testing, analysis of pharmaceuticals and medical diagnostics in the clinical arena. His most successful invention has been the combination of capillary electro-phoresis with mass spectrometry. By the end of the 1990s, Smith's achievements included the electrodynamic ion funnel and a micro-dialysis device for the rapid purification of samples analyzed using mass spectrometry. Other notable contributions have been in the fields of supercritical fluids and related reverse micelle phenomena. On August 22, 2000, Smith demonstrated and patented the electrodynamic ion funnel for highly efficient capture and focusing of ions in gases. He applied it for increasing the sensitivity of ESI-MS. His group has continued to refine and extend ion funnel technology, which is now widely applied in mass spectrometry and ion mobility instrumentation.
Knoxville's first major annexation following the Civil War came in 1869, when it annexed the city of East Knoxville, an area east of First Creek that had incorporated in 1856. In 1883, Knoxville annexed Mechanicsville, which had developed just northwest of the city as a village for Knoxville Iron Company and other factory workers. In the 1870s and 1880s, the development of Knoxville's streetcar system (electrified by William Gibbs McAdoo in 1890) led to the rapid development of suburbs on the city's periphery. Neighborhoods such as Fort Sanders, Fourth and Gill, Old North Knoxville, Happy Holler, and Parkridge, are all rooted in "streetcar suburbs" developed during this period. In 1888, the area now consisting of Fort Sanders and the UT campus were incorporated as the City of West Knoxville, and in 1889, the area now consisting of Old North Knoxville and Fourth and Gill incorporated as the City of North Knoxville. Knoxville annexed both in 1897. In 1907, Parkridge, Chilhowee Park, and adjacent neighborhoods incorporated as Park City. Lonsdale, a factory village northwest of the city, and Mountain View, located south of Park City, incorporated that same year. Oakwood, which developed alongside the Southern Railway's Coster rail yard, was incorporated in 1913. In 1917, Knoxville annexed these four cities, along with the burgeoning suburb of Sequoyah Hills and parts of South Knoxville, effectively more than doubling the city's population, and increasing its land area from 4 to 26 square miles (10 to 67 km2).
Sources: en.wikipedia.org
Respiratory stimulants: carotid chemoreceptor agonists (e.g. doxapram), 5-HT4 agonists (e.g. BIMU8), δ-opioid agonists (e.g. BW373U86) and AMPAkines (e.g. CX717) can all reduce respiratory depression caused by opioids without affecting analgesia, but most of these drugs are only moderately effective or have side effects which preclude use in humans. 5-HT1A agonists such as 8-OH-DPAT and repinotan also counteract opioid-induced respiratory depression, but at the same time reduce analgesia, which limits their usefulness for this application. Opioid antagonists (e.g. naloxone, nalmefene, diprenorphine) The initial 24 hours after opioid administration appear to be the most critical with regard to life-threatening OIRD, but may be preventable with a more cautious approach to opioid use. Patients with cardiac, respiratory disease and/or obstructive sleep apnoea are at increased risk for OIRD.
== Side effects == Side effects of the tablet form in conjunction with levodopa include, in decreasing order of frequency, nausea, hallucinations, confusion, depression, loss of balance, insomnia, increased involuntary movements, agitation, slow or irregular heart rate, delusions, hypertension, new or increased angina pectoris, and syncope. Most of the side effects are due to a high dopamine levels, and can be alleviated by reducing the dose of levodopa. Selegiline can also cause cardiovascular side effects such as orthostatic hypotension, hypertension, atrial fibrillation, and other types of cardiac arrhythmias. The main side effects of the patch form for depression include application-site reactions, insomnia, dry mouth, dizziness, nervousness, and abnormal dreams. The selegiline patch carries a black box warning about a possible increased risk of suicide, especially for young people, as do all antidepressants since 2007. Side effects of selegiline that have been identified as occurring significantly more often than with placebo in meta-analyses for psychiatric disorders have included dry mouth (RRTooltip Risk ratio = 1.58), insomnia (RR = 1.61, NNHTooltip Number needed to harm = 19), and application site reactions with the transdermal form (RR = 1.81, NNH = 7). No significant diarrhea, headache, dizziness, nausea, sexual dysfunction, or weight gain were apparent in these meta-analyses. Selegiline, including in its oral, ODT, and patch forms, has been found to cause hypotension or orthostatic hypotension in some individuals.
=== Magnetic confinement fusion === In fusion devices, such as tokamaks and stellarators, ICRH antennas are installed in the machine vessel to heat the plasma using radio waves with frequencies in the range of the ion cyclotron resonance. ICRH provides localized heating of ions in fusion plasmas, which can generate a large population of energetic particles typically inaccessible with other heating methods (such as electron cyclotron resonance heating or neutral beam injection). The confinement properties of fast ions in plasma is a major research topic in fusion plasma physics.
=== Muscle spindles === The muscle spindle is a proprioceptive organ that lies embedded in the muscle. It is a 1-3mm long encapsulated, fusiform (spindle-shaped) structure comprising contractile intrafusal (inside the spindle) muscle fibers and a central non-contractile region. There are three types of intrafusal fiber: bag I, bag-II and chain, which correspond to the dynamic and static responses of the afferents they influence. Spindles relay information through primary (Group Ia) and secondary (Group II) sensory afferents. Primary afferents innervate nuclear bag and chain intrafusal muscle fibers in the central region and secondary afferents innervate nuclear chain fibers at the ends of the spindle.. Spindles encode extrafusal muscle length, velocity and acceleration. Recent studies suggest that they respond to the force and yank (the first time-derivative of force) exerted on intrafusal muscle. Nonlinear features of muscle spindle responses to muscle stretch include initial bursts, history-dependence, and rate relaxation. Initial bursts occur at the onset of stretch and only last a very short time. History dependence refers to how the response of muscle spindles is affected by past stretch inputs. Rate relaxation refers to how the firing rate of muscle spindles decreases over time when held at a constant length.
Microwave popcorn is a convenience food consisting of unpopped popcorn in an enhanced, sealed paper bag intended to be heated in a microwave oven. In addition to the dried corn, the bags typically contain cooking oil with sufficient saturated fat to solidify at room temperature, one or more seasonings (often salt), and natural or artificial flavorings or both.
Sources: en.wikipedia.org
Phenylalanine Isoleucine Threonine Tryptophan Tyrosine Only leucine and lysine are not glucogenic (they are only ketogenic). Glucogenic and ketogenic amino acids are classified according to the metabolic pathways they enter after being broken down. Glucogenic amino acids can be converted into intermediates that feed the gluconeogenesis metabolic pathway, which produces glucose. When necessary, these amino acids can be used to generate glucose. As previously stated, because they can be transformed into glucose via a variety of metabolic pathways, the majority of amino acids (apart from leucine and lysine) are regarded as glucogenic. Alternatively, the breakdown of ketogenic amino acids results in the ketogenic precursors acetyl-CoA and acetoacetate. These substances undergo a process called ketogenesis that produces ketone bodies like acetoacetate, beta-hydroxybutyrate, and acetone.
After making the necessary adjustments to account for the n0 standard gas density, ion mobilities are often expressed as reduced mobilities. This number can also be described as standard temperature T0 = 273 K and standard pressure p0 = 1013 hPa. Both of these can be found in the table below. Ion concentrations are another term that may be used when referring to ion mobilities. Because of this, the decreased ion mobility is still temperature-dependent, although this adjustment does not consider any impacts other than the reduction in gas density.
=== Development === In at least one knock-out study of the gene, mice without thymosin β4 still had apparently normal embryonic development, and were fertile as adults (in contrast to an earlier knock-out study). This calls into some question the developmental importance of the protein.
=== Immunotherapy === Immunotherapy harnesses the body's immune system to recognize and attack cancer cells or other disease targets. In theranostics, immunotherapeutic approaches can be coupled with diagnostic imaging to assess immune cell infiltration, tumor immunogenicity, and treatment response. Imaging techniques, such as PET and MRI, can provide valuable information about the tumor microenvironment, immune cell dynamics, and response to immunotherapies. Furthermore, theranostic strategies involving the use of radiolabeled immunotherapeutic agents allow for simultaneous imaging and therapy, aiding in patient selection, treatment monitoring, and optimization of immunotherapeutic regimens.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.